Compare · GH vs MEDS
GH vs MEDS
Side-by-side comparison of Guardant Health Inc. (GH) and DataMeds AI Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. GH focuses on Medical Specialities, while MEDS focuses on Other Pharmaceuticals.
- GH is the larger of the two at $19.49B, about 6285.5x MEDS ($3.1M).
- GH has been more active in the news (22 items in the past 4 weeks vs 5 for MEDS).
- GH has more recent analyst coverage (25 ratings vs 1 for MEDS).
- Company
- Guardant Health Inc.
- DataMeds AI Inc.
- Price
- -
- -
- Market cap
- $19.49B
- $3.1M
- 1M return
- -
- -77.82%
- 1Y return
- -
- -98.02%
- Industry
- Medical Specialities
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 22
- 5
- Recent ratings
- 25
- 1
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
DataMeds AI Inc.
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA -based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions.
Latest GH
- Guardant Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Director Azar Alex M Ii converted options into 138 shares, increasing direct ownership by 15% to 1,031 units (SEC Form 4)
- Director Sayer Kevin R was granted 3,149 restricted stock units (SEC Form 4)
- Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New insider Sayer Kevin R claimed no ownership of stock in the company (SEC Form 3)
- Chief Accounting Officer Parks Robert was granted 18,893 restricted stock units (SEC Form 4)
- New insider Parks Robert claimed no ownership of stock in the company (SEC Form 3)
- Guardant Health Prices $500 Million Convertible Senior Notes Offering
- Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
- Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid
Latest MEDS
- DataMEDS AI Releases CEO Letter
- DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
- DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
- DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
- DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
- DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- DataMeds Regains Compliance With NASDAQ Listing Standards
- DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap